Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen

Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other research firms also recently commented on RARE. Guggenheim reduced their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Wedbush lowered their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $57.82.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $25.91 on Friday. The stock has a market capitalization of $2.55 billion, a PE ratio of -4.44 and a beta of 0.35. Ultragenyx Pharmaceutical has a 12-month low of $18.29 and a 12-month high of $39.89. The stock’s 50 day simple moving average is $27.89 and its 200 day simple moving average is $24.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same quarter last year, the company earned ($1.17) EPS. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. On average, research analysts predict that Ultragenyx Pharmaceutical will post -4.42 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. This represents a 17.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director directly owned 21,095 shares in the company, valued at $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 14,292 shares of company stock worth $351,644 in the last three months. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after buying an additional 29,984 shares during the last quarter. Creative Planning purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $454,000. American Century Companies Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $366,000. M&T Bank Corp grew its position in shares of Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 1,192 shares during the period. Finally, Amundi increased its stake in shares of Ultragenyx Pharmaceutical by 1,560.4% in the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after purchasing an additional 93,189 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.